Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias
To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bep...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1986-11, Vol.58 (10), p.1001-1004 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1004 |
|---|---|
| container_issue | 10 |
| container_start_page | 1001 |
| container_title | The American journal of cardiology |
| container_volume | 58 |
| creator | Nestico, Pasquale F. Morganroth, Joel Horowitz, Leonard N. Mulhern, Colleen |
| description | To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bepridil followed by 12 days of bepridil, 400 mg/day. Holter monitoring during therapy showed that 10 patients (48%) had more than a 70% reduction in VPC frequency and 8 of 16 patients (50%) at least a 95% reduction in frequency of nonsustained ventricular tachycardia. Gastrointestinal and central nervous system side effects considered to be mild occurred in 13 patients (62%). One patient had an asymptomatic increase in VPC frequency and another had sustained ventricular tachycardia associated with a loading dose of 900 mg of bepridil. Thus, bepridil has moderate antiarrhythmic efficacy in patients with ventricular arrhythmias, but further definition of its potential for causing proarrhythmia must be determined. |
| doi_str_mv | 10.1016/S0002-9149(86)80027-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77148005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914986800273</els_id><sourcerecordid>77148005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-e8fed03a34c0deb13995090ca891f5670480726f2a87277e33b5ca29a9c2b33f3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1EVZbCT6jkA0JwSGvHSWyfUKn4kir1ANyQrIkzJkZOvNjeSvvvcburvXKy3plnxvZDyCVnV5zx4fo7Y6xtNO_0OzW8VzXIRjwjG66kbrjm4jnZnJAX5GXOf2rkvB_OyXnbCdZ1fEN-fcRt8pMPdN5PKdo5xBqRuphoSQhlwbXQ6OiIq_-90lrexlJrHkLY04BlhkAfaiF5uwuQKKQ078u8eMivyJmDkPH18bwgPz9_-nH7tbm7__Lt9uausULp0qByODEBorNswpELrXummQWluesHyTrFZDu4FpRspUQhxt5Cq0HbdhTCiQvy9rB3m-LfHeZiFp8thgArxl02UvK6gvUV7A-gTTHnhM7Uzy-Q9oYz82jVPFk1j8qMGsyTVSPq3OXxgt244HSaOmqs_TfHPmQLwSVYrc8nTGo1iK6t2IcDhlXGg8dksvW4Wpx8QlvMFP1_HvIPR0eUzA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77148005</pqid></control><display><type>article</type><title>Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Nestico, Pasquale F. ; Morganroth, Joel ; Horowitz, Leonard N. ; Mulhern, Colleen</creator><creatorcontrib>Nestico, Pasquale F. ; Morganroth, Joel ; Horowitz, Leonard N. ; Mulhern, Colleen</creatorcontrib><description>To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bepridil followed by 12 days of bepridil, 400 mg/day. Holter monitoring during therapy showed that 10 patients (48%) had more than a 70% reduction in VPC frequency and 8 of 16 patients (50%) at least a 95% reduction in frequency of nonsustained ventricular tachycardia. Gastrointestinal and central nervous system side effects considered to be mild occurred in 13 patients (62%). One patient had an asymptomatic increase in VPC frequency and another had sustained ventricular tachycardia associated with a loading dose of 900 mg of bepridil. Thus, bepridil has moderate antiarrhythmic efficacy in patients with ventricular arrhythmias, but further definition of its potential for causing proarrhythmia must be determined.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(86)80027-3</identifier><identifier>PMID: 2430441</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antiarythmic agents ; Bepridil ; Biological and medical sciences ; Calcium Channel Blockers - administration & dosage ; Calcium Channel Blockers - therapeutic use ; Cardiac Complexes, Premature - drug therapy ; Cardiovascular system ; Clinical Trials as Topic ; Electrocardiography ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Monitoring, Physiologic ; Pharmacology. Drug treatments ; Pyrrolidines - administration & dosage ; Pyrrolidines - therapeutic use ; Tachycardia - drug therapy</subject><ispartof>The American journal of cardiology, 1986-11, Vol.58 (10), p.1001-1004</ispartof><rights>1986</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-e8fed03a34c0deb13995090ca891f5670480726f2a87277e33b5ca29a9c2b33f3</citedby><cites>FETCH-LOGICAL-c389t-e8fed03a34c0deb13995090ca891f5670480726f2a87277e33b5ca29a9c2b33f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9149(86)80027-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7986342$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2430441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nestico, Pasquale F.</creatorcontrib><creatorcontrib>Morganroth, Joel</creatorcontrib><creatorcontrib>Horowitz, Leonard N.</creatorcontrib><creatorcontrib>Mulhern, Colleen</creatorcontrib><title>Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bepridil followed by 12 days of bepridil, 400 mg/day. Holter monitoring during therapy showed that 10 patients (48%) had more than a 70% reduction in VPC frequency and 8 of 16 patients (50%) at least a 95% reduction in frequency of nonsustained ventricular tachycardia. Gastrointestinal and central nervous system side effects considered to be mild occurred in 13 patients (62%). One patient had an asymptomatic increase in VPC frequency and another had sustained ventricular tachycardia associated with a loading dose of 900 mg of bepridil. Thus, bepridil has moderate antiarrhythmic efficacy in patients with ventricular arrhythmias, but further definition of its potential for causing proarrhythmia must be determined.</description><subject>Antiarythmic agents</subject><subject>Bepridil</subject><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - administration & dosage</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiac Complexes, Premature - drug therapy</subject><subject>Cardiovascular system</subject><subject>Clinical Trials as Topic</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monitoring, Physiologic</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrrolidines - administration & dosage</subject><subject>Pyrrolidines - therapeutic use</subject><subject>Tachycardia - drug therapy</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1EVZbCT6jkA0JwSGvHSWyfUKn4kir1ANyQrIkzJkZOvNjeSvvvcburvXKy3plnxvZDyCVnV5zx4fo7Y6xtNO_0OzW8VzXIRjwjG66kbrjm4jnZnJAX5GXOf2rkvB_OyXnbCdZ1fEN-fcRt8pMPdN5PKdo5xBqRuphoSQhlwbXQ6OiIq_-90lrexlJrHkLY04BlhkAfaiF5uwuQKKQ078u8eMivyJmDkPH18bwgPz9_-nH7tbm7__Lt9uausULp0qByODEBorNswpELrXummQWluesHyTrFZDu4FpRspUQhxt5Cq0HbdhTCiQvy9rB3m-LfHeZiFp8thgArxl02UvK6gvUV7A-gTTHnhM7Uzy-Q9oYz82jVPFk1j8qMGsyTVSPq3OXxgt244HSaOmqs_TfHPmQLwSVYrc8nTGo1iK6t2IcDhlXGg8dksvW4Wpx8QlvMFP1_HvIPR0eUzA</recordid><startdate>19861101</startdate><enddate>19861101</enddate><creator>Nestico, Pasquale F.</creator><creator>Morganroth, Joel</creator><creator>Horowitz, Leonard N.</creator><creator>Mulhern, Colleen</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19861101</creationdate><title>Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias</title><author>Nestico, Pasquale F. ; Morganroth, Joel ; Horowitz, Leonard N. ; Mulhern, Colleen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-e8fed03a34c0deb13995090ca891f5670480726f2a87277e33b5ca29a9c2b33f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Antiarythmic agents</topic><topic>Bepridil</topic><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - administration & dosage</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiac Complexes, Premature - drug therapy</topic><topic>Cardiovascular system</topic><topic>Clinical Trials as Topic</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monitoring, Physiologic</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrrolidines - administration & dosage</topic><topic>Pyrrolidines - therapeutic use</topic><topic>Tachycardia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nestico, Pasquale F.</creatorcontrib><creatorcontrib>Morganroth, Joel</creatorcontrib><creatorcontrib>Horowitz, Leonard N.</creatorcontrib><creatorcontrib>Mulhern, Colleen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nestico, Pasquale F.</au><au>Morganroth, Joel</au><au>Horowitz, Leonard N.</au><au>Mulhern, Colleen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1986-11-01</date><risdate>1986</risdate><volume>58</volume><issue>10</issue><spage>1001</spage><epage>1004</epage><pages>1001-1004</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bepridil followed by 12 days of bepridil, 400 mg/day. Holter monitoring during therapy showed that 10 patients (48%) had more than a 70% reduction in VPC frequency and 8 of 16 patients (50%) at least a 95% reduction in frequency of nonsustained ventricular tachycardia. Gastrointestinal and central nervous system side effects considered to be mild occurred in 13 patients (62%). One patient had an asymptomatic increase in VPC frequency and another had sustained ventricular tachycardia associated with a loading dose of 900 mg of bepridil. Thus, bepridil has moderate antiarrhythmic efficacy in patients with ventricular arrhythmias, but further definition of its potential for causing proarrhythmia must be determined.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2430441</pmid><doi>10.1016/S0002-9149(86)80027-3</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1986-11, Vol.58 (10), p.1001-1004 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77148005 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antiarythmic agents Bepridil Biological and medical sciences Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - therapeutic use Cardiac Complexes, Premature - drug therapy Cardiovascular system Clinical Trials as Topic Electrocardiography Female Humans Male Medical sciences Middle Aged Monitoring, Physiologic Pharmacology. Drug treatments Pyrrolidines - administration & dosage Pyrrolidines - therapeutic use Tachycardia - drug therapy |
| title | Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T16%3A50%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bepridil%20hydrochloride%20for%20treatment%20of%20benign%20or%20potentially%20lethal%20ventricular%20arrhythmias&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Nestico,%20Pasquale%20F.&rft.date=1986-11-01&rft.volume=58&rft.issue=10&rft.spage=1001&rft.epage=1004&rft.pages=1001-1004&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(86)80027-3&rft_dat=%3Cproquest_cross%3E77148005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77148005&rft_id=info:pmid/2430441&rft_els_id=S0002914986800273&rfr_iscdi=true |